Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time? A structured review

David A Fishbain, Dana Fishbain, John E Lewis, R. B. Cutler, Brandly Cole, H. L. Rosomoff, R. Steele Rosomoff

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Study Design. This is a structured review of genomic (genetic) testing for enzymes of drug metabolism. Objectives. Recently, industry began offering genomic testing for enzymes of drug metabolism. As such, the objective of this review was to determine if genomic testing for enzymes of drug metabolism has any imminent clinical relevance for the practice of pain medicine. Methods. Relevant references relating to pharmacogenetics, pharmacogenomics, and the metabolizing of drugs used in pain medicine by cytochrome P-450 enzymes were located and reviewed in detail. The P-450 enzymes that metabolize each drug and whether that drug had been identified as being subject to a clinical consequence of a genetic polymorphism of the P-450 enzyme involved in its metabolism were placed into tabular form. Results of Data Synthesis. 1) For a large number of drugs, we do not yet know which cytochrome P-450 enzymes are involved in their metabolism; 2) For a large number of drugs, the consequences of a P-450 genetic polymorphism have yet to be determined; 3) Genetic polymorphism can lead to important potential clinical consequences for some opioids, anticonvulsants (phenytoin), benzodiazepines (diazepam), muscle relaxants (succinylcholine), antidepressants (imipramine, nortriptyline, venlafaxine), typical neuroleptics, alcohol, antihypertensives (propranolol, timolol), local anesthetics (procainamide), L-dopa, nicotine, and warfarin. Based on these results, factors for and against using genomic testing were reviewed. Conclusions/Recommendations. It was concluded that genomic testing for enzymes of drug metabolism has significant potential for improving the efficacy of drug treatment and reducing adverse drug reactions. Recommendations for when such testing would be useful are outlined.

Original languageEnglish
Pages (from-to)81-93
Number of pages13
JournalPain Medicine
Volume5
Issue number1
DOIs
StatePublished - Mar 1 2004

Fingerprint

Genetic Testing
Medicine
Pain
Enzymes
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Genetic Polymorphisms
Pharmacogenetics
Nortriptyline
Procainamide
Timolol
Succinylcholine
Imipramine
Phenytoin
Levodopa
Warfarin
Diazepam
Local Anesthetics
Drug-Related Side Effects and Adverse Reactions
Benzodiazepines

Keywords

  • Cytochrome P-450 enzymes
  • Drug metabolism
  • Genetic polymorphism
  • Genomic testing
  • Pharmacogenetics
  • Pharmacogenomics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Genetic testing for enzymes of drug metabolism : Does it have clinical utility for pain medicine at the present time? A structured review. / Fishbain, David A; Fishbain, Dana; Lewis, John E; Cutler, R. B.; Cole, Brandly; Rosomoff, H. L.; Rosomoff, R. Steele.

In: Pain Medicine, Vol. 5, No. 1, 01.03.2004, p. 81-93.

Research output: Contribution to journalArticle

Fishbain, David A ; Fishbain, Dana ; Lewis, John E ; Cutler, R. B. ; Cole, Brandly ; Rosomoff, H. L. ; Rosomoff, R. Steele. / Genetic testing for enzymes of drug metabolism : Does it have clinical utility for pain medicine at the present time? A structured review. In: Pain Medicine. 2004 ; Vol. 5, No. 1. pp. 81-93.
@article{644fa482cda14a9c8b80fa9f92ab194c,
title = "Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time? A structured review",
abstract = "Study Design. This is a structured review of genomic (genetic) testing for enzymes of drug metabolism. Objectives. Recently, industry began offering genomic testing for enzymes of drug metabolism. As such, the objective of this review was to determine if genomic testing for enzymes of drug metabolism has any imminent clinical relevance for the practice of pain medicine. Methods. Relevant references relating to pharmacogenetics, pharmacogenomics, and the metabolizing of drugs used in pain medicine by cytochrome P-450 enzymes were located and reviewed in detail. The P-450 enzymes that metabolize each drug and whether that drug had been identified as being subject to a clinical consequence of a genetic polymorphism of the P-450 enzyme involved in its metabolism were placed into tabular form. Results of Data Synthesis. 1) For a large number of drugs, we do not yet know which cytochrome P-450 enzymes are involved in their metabolism; 2) For a large number of drugs, the consequences of a P-450 genetic polymorphism have yet to be determined; 3) Genetic polymorphism can lead to important potential clinical consequences for some opioids, anticonvulsants (phenytoin), benzodiazepines (diazepam), muscle relaxants (succinylcholine), antidepressants (imipramine, nortriptyline, venlafaxine), typical neuroleptics, alcohol, antihypertensives (propranolol, timolol), local anesthetics (procainamide), L-dopa, nicotine, and warfarin. Based on these results, factors for and against using genomic testing were reviewed. Conclusions/Recommendations. It was concluded that genomic testing for enzymes of drug metabolism has significant potential for improving the efficacy of drug treatment and reducing adverse drug reactions. Recommendations for when such testing would be useful are outlined.",
keywords = "Cytochrome P-450 enzymes, Drug metabolism, Genetic polymorphism, Genomic testing, Pharmacogenetics, Pharmacogenomics",
author = "Fishbain, {David A} and Dana Fishbain and Lewis, {John E} and Cutler, {R. B.} and Brandly Cole and Rosomoff, {H. L.} and Rosomoff, {R. Steele}",
year = "2004",
month = "3",
day = "1",
doi = "10.1111/j.1526-4637.2004.04007.x",
language = "English",
volume = "5",
pages = "81--93",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Genetic testing for enzymes of drug metabolism

T2 - Does it have clinical utility for pain medicine at the present time? A structured review

AU - Fishbain, David A

AU - Fishbain, Dana

AU - Lewis, John E

AU - Cutler, R. B.

AU - Cole, Brandly

AU - Rosomoff, H. L.

AU - Rosomoff, R. Steele

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Study Design. This is a structured review of genomic (genetic) testing for enzymes of drug metabolism. Objectives. Recently, industry began offering genomic testing for enzymes of drug metabolism. As such, the objective of this review was to determine if genomic testing for enzymes of drug metabolism has any imminent clinical relevance for the practice of pain medicine. Methods. Relevant references relating to pharmacogenetics, pharmacogenomics, and the metabolizing of drugs used in pain medicine by cytochrome P-450 enzymes were located and reviewed in detail. The P-450 enzymes that metabolize each drug and whether that drug had been identified as being subject to a clinical consequence of a genetic polymorphism of the P-450 enzyme involved in its metabolism were placed into tabular form. Results of Data Synthesis. 1) For a large number of drugs, we do not yet know which cytochrome P-450 enzymes are involved in their metabolism; 2) For a large number of drugs, the consequences of a P-450 genetic polymorphism have yet to be determined; 3) Genetic polymorphism can lead to important potential clinical consequences for some opioids, anticonvulsants (phenytoin), benzodiazepines (diazepam), muscle relaxants (succinylcholine), antidepressants (imipramine, nortriptyline, venlafaxine), typical neuroleptics, alcohol, antihypertensives (propranolol, timolol), local anesthetics (procainamide), L-dopa, nicotine, and warfarin. Based on these results, factors for and against using genomic testing were reviewed. Conclusions/Recommendations. It was concluded that genomic testing for enzymes of drug metabolism has significant potential for improving the efficacy of drug treatment and reducing adverse drug reactions. Recommendations for when such testing would be useful are outlined.

AB - Study Design. This is a structured review of genomic (genetic) testing for enzymes of drug metabolism. Objectives. Recently, industry began offering genomic testing for enzymes of drug metabolism. As such, the objective of this review was to determine if genomic testing for enzymes of drug metabolism has any imminent clinical relevance for the practice of pain medicine. Methods. Relevant references relating to pharmacogenetics, pharmacogenomics, and the metabolizing of drugs used in pain medicine by cytochrome P-450 enzymes were located and reviewed in detail. The P-450 enzymes that metabolize each drug and whether that drug had been identified as being subject to a clinical consequence of a genetic polymorphism of the P-450 enzyme involved in its metabolism were placed into tabular form. Results of Data Synthesis. 1) For a large number of drugs, we do not yet know which cytochrome P-450 enzymes are involved in their metabolism; 2) For a large number of drugs, the consequences of a P-450 genetic polymorphism have yet to be determined; 3) Genetic polymorphism can lead to important potential clinical consequences for some opioids, anticonvulsants (phenytoin), benzodiazepines (diazepam), muscle relaxants (succinylcholine), antidepressants (imipramine, nortriptyline, venlafaxine), typical neuroleptics, alcohol, antihypertensives (propranolol, timolol), local anesthetics (procainamide), L-dopa, nicotine, and warfarin. Based on these results, factors for and against using genomic testing were reviewed. Conclusions/Recommendations. It was concluded that genomic testing for enzymes of drug metabolism has significant potential for improving the efficacy of drug treatment and reducing adverse drug reactions. Recommendations for when such testing would be useful are outlined.

KW - Cytochrome P-450 enzymes

KW - Drug metabolism

KW - Genetic polymorphism

KW - Genomic testing

KW - Pharmacogenetics

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=1642485099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642485099&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2004.04007.x

DO - 10.1111/j.1526-4637.2004.04007.x

M3 - Article

C2 - 14996240

AN - SCOPUS:1642485099

VL - 5

SP - 81

EP - 93

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 1

ER -